# Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pemetrexed-versus-gefitinib-as-a-second-line-treatment-in-advanced-nonsquamous/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Qing Zhou,Ying Cheng,Jin‐Ji Yang,Mingfang Zhao,L. Zhang,X.-C. Zhang,Zhendong Chen,Hong‐Hong Yan,Yong Song,Juxiang Chen,Weineng Feng,Chong‐Rui Xu,Z. Wang,H.-J. Chen,Wen‐Zhao Zhong,Y.-P. Liu,Yi‐Long Wu |
| Citations | 69 |
| DOI | 10.1093/annonc/mdu463 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753419369091/pdf |
| OpenAlex ID | https://openalex.org/W2040318364 |
| PMID | 25281710 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Weineng Feng](https://scholariq.org/researchers/weineng-feng/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.